Goldman Sachs upgrades BioNTech to Buy, highlighting the potential of its cancer drug BNT327 and forecasting strong future ...

Fintel reports that on November 8, 2024, Goldman Sachs upgraded their outlook for BioNTech SE - Depositary Receipt () ...

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $127.53, ...

In a report released yesterday, Chris Shibutani from Goldman Sachs upgraded BioNTech SE (BNTX – Research Report) to a Buy, with a price ...

Meanwhile, among the sector's biggest decliners were hospital operators, with HCA Healthcare Inc.'s stock (HCA) shedding 4.6%, Universal Health Services Inc. shares (UHS) falling 3.7% and shares of ...

Despite the potential in oncology, BNTX's current valuation is high relative to its non-COVID revenue prospects, warranting a ...

Third Quarter 2024 Results Key Financial Results Revenue: €1.24b (up 39% from 3Q 2023).

BioNTech SE (BNTX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Yaron Werber ...

Operator Welcome to BioNTech's third quarter 2024 earnings call. I would like to hand the call over to Michael Horowicz ...

On Monday, BioNTech SE (NASDAQ:BNTX) reported third-quarter revenues of 1.244 billion euros (or $1.36 billion), up from 895.3 ...